Executive Search OTC Pharma & Consumer Health
FMCG meets Pharma. The self-medication market demands a completely new pace. Established players often become complacent and manage dormant portfolios. Meanwhile, smart digital D2C brands are stealing market share with a fraction of the marketing costs. Those who want to grow here must combine the extreme speed of consumer goods with the stringent compliance requirements of the pharmaceutical industry. This primarily affects your core roles in the commercial sector. A vacant position in a key strategic role carries significant risks. We mitigate your P&L risk through exclusive headhunting. In cases of urgent need for action, we also provide short-term interim management capacity.
Market Dynamics with Consequences:
The Battle for Distribution Channels
The German market for self-medication is changing rapidly. The traditional pharmacy model is losing ground every day. The number of brick-and-mortar pharmacies has fallen to a historic low of 16,601 (as of January 2026). I already pointed out this trend in my regionally differentiated analysis of pharmacy closures in 2023. The German Medical Journal (Deutsches Ärzteblatt) picked up on these findings.
This is a critical situation for pharmaceutical companies. If local pharmacies disappear, they will inevitably face the fierce oligopoly of drugstores and grocery retailers. In the mass market, retailers dictate the terms.
All major manufacturers in Germany primarily grow through mail-order sales. This channel already controls 24 percent of total OTC sales. Internationalization is another significant driver. In Asian countries, the "Made in Germany" label, combined with genuine clinical evidence, carries immense value. German pharmaceutical companies with scientifically sound portfolios have enormous growth potential here.
The Search for Growth:
Dietary Supplements and the Regulatory Tightrope Walk
The requirements for traditional-use registrations for herbal medicinal products (phytopharmaceuticals) have been drastically tightened. The number of marketable phytopharmaceuticals has collapsed by over 50 percent to just under 1,100.
Well-established-use authorizations remain stable, but the corridor is narrow and clinically demanding. New full marketing authorizations are economically unviable.
The industry is moving en masse into dietary supplements. Faster market access, no marketing authorization required, only notification. In return, severely restricted health claims and food safety inspections that challenge nearly every second sample.
The market adapts new trends like collagen or microbiome health in months, not years. 75 percent of the adult population already consume dietary supplements. The growth is real. But the rules of the game are different from the traditional pharmaceutical business.
Health claims are aggressively tested, cease-and-desist letters are priced-in operating costs, regulatory grey areas are part of the competition. Anyone who does not understand this has no place in this industry. Anyone who pushes it too far risks audits, product recalls, and market exclusion.
To succeed in these new market conditions, companies need modern leaders who master both sides. FMCG speed in product launches, pharmaceutical discipline in compliance and communication.
Pharma:
Where is the love?
We see every day what established brands are failing at. Effective heritage brands are literally gathering dust on the shelf.
What is missing are the hybrid managers to develop strategies that successfully combine pharmaceutical regulation with FMCG speed.
Brands = emotions.
Are your brands lovebrands?
Executive Search Marketing Head
& Senior Product Manager Consumer Health
Creativity and boldness are your new currencies. Aggressive marketing from pure lifestyle brands often outshines established pharma brands. We recruit marketing leaders and senior product managers who break new ground. We source profiles that translate scientific data into emotionally compelling, high-impact messaging for the target audience. They bring dormant brands back to life.
Executive Search Head of Sales &
High-Impact Key Account Manager
Broad-based field sales are simply no longer economically viable. Cross-industry benchmarks and analyses show that a single in-person field sales visit costs between 150 and 200 euros depending on the structure. These costs completely burn through your margins in the mass-market business. We place sales managers who master strict sales force management and establish new omnichannel concepts. For negotiations with the oligopolies, we fill smart key account manager positions with measurable impact on your revenues in wholesale, Amazon, and major mail-order retail chains."
You've used 75% of your weekly limitGet more usage
Talent market
OTC-Pharma &
Consumer Healthcare
in Germany
The search for hybrid leaders who understand pharmaceutical structures and deliver at the pace of the FMCG industry takes approximately four months on average. Four months that directly translate into growth in an extremely seasonal business.
Pure FMCG marketers often fail in pharmaceutical structures due to the regulatory culture. Not because they are weak, but because the world is different. The cost of hiring the wrong person can then amount to two to three times their annual salary. Conversely, those who rely on pure pharmaceutical bureaucrats risk losing the market to faster competitors and new D2C nutritional supplement startups.
The right candidate is comfortable in both worlds. These profiles are rare, don't change jobs through job boards, and must be actively approached.
We activate passive candidates with our personalized direct search. We assess professional expertise and eliminate cultural conflicts through structured aptitude diagnostics before a profile lands on your desk.
Examples of mandates
Executive Search Consumer Health & OTC Pharma
We measure our success by the impact of the candidates we place. A venture capital-backed pharmaceutical company demanded the immediate revival of dormant listings for traditional brands. The products were essentially gathering dust in the pharmacy cooperative systems, lacking any active sales pressure. For this placement, we deliberately left the traditional pharmaceutical environment. We focused on candidates from the cosmetics and FMCG sectors. We appointed a sales manager with a clear FMCG mindset who brought emotion to sales while simultaneously ensuring regulatory compliance. The result was double-digit sales growth and the measurable reactivation of distribution at the point of sale. Read the complete business case here: Renaissance of Classics in OTC Sales.
Our Executive Search Approach
We avoid empty promises and mass-produced solutions. We analyze your individual bottleneck and your specific objectives. Do you want to revitalize a traditional brand? Are you planning growth through new licenses? Are you preparing for your next international expansion?
As a specialized boutique agency, we speak plainly. We don't meet quotas based on internal spreadsheets. If a profile in the desired form doesn't exist on the market, we'll tell you directly. We never send unsuitable candidates to artificially inflate the number of applicants. We solve your problem with the best available option.
We assess the candidates' skills very specifically. Can brand managers with a modern understanding of branding and in-depth relaunch knowledge bring a traditional brand back into the market?
We critically examine how marketing managers turn scientifically positioned products into genuine love brands.
We analyze how Commercial Heads can successfully launch in drugstores and grocery stores without alienating their core target group of pharmacists.
Our fundamental conviction is clear: Consumer Health needs more FMCG speed, but with calculated risk.
We closely monitor the entire process. This ensures your growth and minimizes the risk of costly hiring mistakes. Let's define the perfect recruiting strategy for your project in a personal consultation.
The direct and indirect costs of a bad appointment at the management level amount to two to three times the annual salary.
Managers from the traditional consumer goods sector often possess precisely the qualities that the OTC and consumer health markets urgently need: speed, brand understanding, experience in performance marketing, and the ability to bring products to market quickly and at scale. Many of the most successful executives in the consumer health sector began their careers in FMCG companies. However, the transition is only successful if, in addition to commercial drive, a person also has a genuine understanding of the regulatory framework.
This framework is complex and multifaceted. The German Medicines Advertising Act regulates every product-related advertising claim. The EU Health Claims Regulation stipulates which health-related claims are permitted on packaging and in campaigns. The Novel Food Regulation determines which ingredients may be placed on the market at all. And the Food Supplements Regulation defines strict requirements for labeling and composition.
Official inspections demonstrate how quickly things can go wrong when this interplay is underestimated. The Lower Saxony State Office for Consumer Protection and Food Safety documents complaint rates of up to 64 percent for food supplements. The most frequent reasons are misleading information, labeling deficiencies, the use of unauthorized novel foods, and inadmissible health claims. According to consumer protection agencies, nationwide, on average, almost every second sample is found to be defective.
For us, this means we deliberately seek out individuals with an FMCG background. Crucially, however, we meticulously assess during the personal selection process whether a candidate can bridge both worlds: commercial pressure and regulatory awareness, speed and diligence. This assessment is precisely what distinguishes a leader who transforms your OTC division from an expensive miscast.
The pharmacy market is undergoing a structural transformation. According to Insight Health, mail-order pharmacies now account for 32 percent of the over-the-counter (OTC) product range. In 2024, the online OTC market grew by more than 11 percent, while brick-and-mortar pharmacies only saw an increase of 2.4 percent. The introduction of mandatory electronic prescriptions at the beginning of 2024 and the Card Link system in May 2024 is further accelerating this shift. For a Head of E-Commerce in this market, this means that the role is essentially a strategic sales position with three key areas of responsibility.
The first step is negotiating with large online pharmacies such as Redcare Pharmacy (formerly Shop Apotheke), DocMorris, and Apodiscounter. This involves discussions about product placement, advertising subsidies, and terms and conditions. Additionally, there's the need to understand marketplaces like Amazon, where sales of pharmacy products alone are projected to reach nearly €500 million by 2025.
The second area of focus is gaining increasing importance: the development of in-house direct-to-consumer channels in order to specifically reduce dependence on mail-order pharmacies.
The third area of focus is only just emerging, but it will fundamentally change the role of online marketplaces. Since the beginning of 2026, US users have been able to purchase products directly through ChatGPT. OpenAI has introduced the so-called Instant Checkout, which already integrates Shopify merchants, Walmart, and other providers. Expansion into further markets is planned for 2026. Meta has been testing a comparable shopping function since March 2026. For OTC manufacturers, this means: those who don't optimize their product data for AI-powered commerce simply won't be present in this new channel.
The profile required for this role combines strong negotiation skills on the platform side with the ability to build proprietary digital sales channels and to tap into new technology channels early on. We identify individuals who combine commercial drive with regulatory foresight and digital vision.
In executive search for the consumer health and pharmaceutical markets, two models essentially compete: large international consulting firms and specialized boutiques. Both have their place. However, decision-makers should take a close look at how the search is actually conducted.
At large consulting firms like Egon Zehnder, Spencer Stuart, or Kienbaum, the mandate is often won by an experienced partner who impresses with in-depth industry knowledge during the initial meeting. The operational search is then frequently handled by junior researchers or associates who derive the job profile from a briefing document, not from their own market experience. However, the crucial asset of a recruitment consultancy in the regulated pharmaceutical sector is its personal network at the decision-making level. This network is always tied to a specific individual. It cannot be delegated, transferred to a database, or activated by a junior consultant. If the partner who sells the mandate is not the same one who approaches and evaluates the candidates, this very advantage is lost. What remains is a strong brand name on the invoice. For the hiring manager, this is a safe bet. Whether it's the best choice for filling the position is another matter entirely.
Our model is structured differently. Each mandate is handled by a single point of contact. The seniority that wins the engagement is the same person who conducts the search and evaluates the candidates. The search relies on three access points, which only in combination unlock the hidden candidate market: a personal network at the management level, cultivated over years; so-called multipliers—well-connected industry insiders who open doors that would remain closed to a cold approach; and a technology-supported direct search. Personal networks alone don't scale. That's why we supplement them with data-driven sourcing methods and digital market analysis to capture the entire relevant candidate pool, not just those we know personally. Furthermore, we possess in-depth regulatory knowledge. We understand the difference between a health claim under the Health Claims Regulation (HCVO) and a product-related statement under the German Medicines Advertising Act not from a briefing, but from years of experience in this market. This enables us to evaluate candidates not only based on their resumes, but also to assess whether they truly master the specific complexities at the intersection of consumer goods and pharmaceuticals.
Reaching passively searching executives in regulated markets requires, in practice, a combination of several approaches. The first approach is a personal network built up over years at the decision-making level, which establishes trust even before a concrete mandate is on the table. The second approach involves so-called multipliers. These are well-connected industry insiders who are not candidates themselves, but whose positions open doors to individuals who would be inaccessible through a cold approach. The third approach is a systematic direct search, in which we selectively identify and discreetly qualify profiles for a specific mandate. Only the combination of these three approaches reaches candidates who remain invisible to internal recruiting teams or generalist recruitment agencies.
According to the Center for Executive Succession at the University of South Carolina, approximately 40 percent of all external executive appointments fail within the first 18 months. The cost of such a misplacement ranges from two to five times the annual salary for management positions and up to ten times for C-level roles. In a regulated market like consumer health, regulatory follow-up costs are added to the mix: incorrect decisions regarding advertising, labeling, or product strategy can trigger cease-and-desist letters, sales stoppages, or product recalls.
A strong rhetorical performance in an interview is not enough to control this risk. Managers with a purely consumer goods background, in particular, can be excellent at selling themselves. Whether they can succeed in the highly regulated pharmaceutical environment is often not apparent from a single interview.
Therefore, we offer two validated diagnostic procedures as optional components of the selection process, addressing different dimensions of risk. The first is a personality profiling based on the Big Five model. It is the most empirically validated personality model in work and organizational psychology. Large-scale meta-analyses show that conscientiousness, in particular, is the strongest non-cognitive predictor of job performance. This factor is especially revealing at the interface between consumer goods and pharmaceuticals: It shows whether a candidate acts impulsively and purely sales-driven, or whether they have a structured work style that views regulatory guidelines not as a hindrance, but as a framework for action.
The second method is a core values analysis. While the Big Five model measures personality structure, i.e., how someone behaves, values analysis captures the underlying motivations, i.e., why someone acts the way they do. Scientific research on value systems, particularly the work of Shalom Schwartz, shows that the alignment between a candidate's personal values and the company culture is a strong predictor of job satisfaction, engagement, and long-term retention. A candidate can be professionally and personally excellent and still fail if their value system doesn't align with the company culture.
We will discuss with you individually which of the two methods is the right one for your specific mandate. In some cases, the focus is on individual performance, in which case Big Five profiling is the appropriate tool. In other cases, such as filling a key role in a company with a strong values-based culture, core values analysis provides more relevant insights. In both cases, we measurably reduce the risk of a costly hiring mistake.
Andris Consulting fills leadership positions and selected senior specialist roles (Individual Contributors) along the entire value chain in the consumer health and OTC pharmaceutical markets. The focus is on roles that have a strategic impact on revenue, market access, or regulatory compliance.
In the area of general management and commercial leadership, we fill positions in management, head of commercial, head of sales, and head of marketing and communication.
In sales, we identify high-impact key account managers who conduct complex negotiations with purchasing groups, mail-order pharmacies, or grocery retailers. In digital sales, we seek e-commerce managers who strategically manage the growing mail-order pharmacy sector and platforms like Amazon.
In the marketing department, we employ Senior Product Managers and Brand Managers who develop brand strategies and implement them within the regulatory framework of the pharmaceutical market.
In the area of business development and licensing, we identify executives who are responsible for portfolio decisions, negotiate license agreements, evaluate acquisition targets, and develop new product categories.
In the regulatory environment, we fill Regulatory Lead positions to ensure compliance with the German Medicines Advertising Act, the Health Claims Regulation and the Food Supplements Regulation.
What all these roles have in common is that they require candidates who combine commercial thinking with an understanding of the regulatory specifics of the pharmaceutical market. This hybrid profile is precisely what we are looking for. In addition, we also support our clients, when needed, in filling selected corporate functions in HR, IT, and Finance within the consumer health industry. In cases of urgent need, we also provide short-term interim management capacity.
- Error: empty slot
- Error: empty slot
This is a perfectly valid business question. At first glance, the success-based model seems less risky: no hiring, no costs. However, analyzing the economic incentives reveals a classic principal-agent problem. In the contingency model, the consultant bears the full cost risk. Their economic imperative is speed over thoroughness. They focus on candidates who are readily available. If the search becomes complex, their model forces them to divert resources. Your interests and theirs are asymmetrical: you want the best, the recruiter needs the fastest. The committed capital in the mandate model aligns these interests. ANDRIS CONSULTING is paid to penetrate the entire market and also activate candidates who are not actively searching. Identifying latent motivations for change and cultural fit requires resources, sensitivity, and seniority; in a pure recruitment business, this effort would simply be uneconomical. The retainer is not an additional fee, but an investment in process reliability. The cost-per-hire remains the same. The total cost of ownership is generally lower in the mandate model, provided you have the right recruitment consultant on your side.